Urogynecology (Hagerstown, Md.)最新文献

{"title":"Multidisciplinary Surgical Management of Vaginal Evisceration: A Case Report.","authors":"David Lee, Matthew Ramsey, Emily Cerier, Rachel Van Doorn, Gregory Dumanian, Nabil Issa, Julia Geynisman-Tan","doi":"10.1097/SPV.0000000000001720","DOIUrl":"https://doi.org/10.1097/SPV.0000000000001720","url":null,"abstract":"<p><strong>Abstract: </strong>Vaginal dehiscence with evisceration is a surgical emergency where all cases are surgically managed. However, identifying the optimal approach in a patient with a history of prior chemoradiation and multiple native-tissue pelvic reconstructive surgical procedures may be challenging. We present here a multidisciplinary case of a 74-year-old patient where flap and graft material placement were utilized as part of her management. She presented as a transfer from an outside hospital for vaginal evisceration of small bowel contents. She was hemodynamically stable, and physical examination revealed 14 cm of edematous, nonreducible, hyperemic bowel protruding beyond her introitus. General surgery and plastic surgery services were consulted for multidisciplinary management. She underwent urgent exploratory laparotomy with an oblique rectus abdominus flap (performed by plastic surgery), small bowel resection and right hemicolectomy (by general surgery), and closure of the distal posterior vaginal wall dehiscence site with placement of a saline-reconstituted decellularized fish skin xenograft within the vaginal defect (by urogynecology). Her postoperative course was uncomplicated, and she was discharged home on postoperative day (POD) 11. She was recovered and asymptomatic at her 4-week postoperative follow-up visit, where she declined scheduling further follow-up appointments. In conclusion, vaginal incision dehiscence with evisceration is best approached early on in a multidisciplinary manner. Select patients, such as those with an extensive pelvic surgical history, multiple vulnerable vaginal incision lines, and history of recurrent prolapse may benefit from consideration of flap placement and application of graft material for wound healing and surgical site integrity at the time of repair.</p>","PeriodicalId":75288,"journal":{"name":"Urogynecology (Hagerstown, Md.)","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145245968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex Disparities in Normal Pressure Hydrocephalus Diagnosis and Urinary Outcomes.","authors":"Nishanth S Sadagopan, Rishi Jain, Rahul K Chaliparambil, Rushmin Khazanchi, Joshua M Rosenow, Matthew B Potts, James P Chandler, Matthew C Tate, Stephen T Magill, Julia Geynisman-Tan","doi":"10.1097/SPV.0000000000001737","DOIUrl":"https://doi.org/10.1097/SPV.0000000000001737","url":null,"abstract":"<p><strong>Importance: </strong>Idiopathic normal pressure hydrocephalus (iNPH) is characterized by dementia, gait disturbance, and urinary incontinence (UI). While gait and cognitive impairments trigger a focused workup, UI is often excused by female patients and doctors as normal aging in women.</p><p><strong>Objectives: </strong>The objectives of this study were to evaluate sex differences in time from UI documentation to iNPH diagnosis and describe differences in postoperative UI outcomes following ventriculoperitoneal shunt placement.</p><p><strong>Study design: </strong>This was a single-center, retrospective study of patients treated for iNPH who presented with the complete triad of symptoms. The primary outcome was the time from UI documentation to iNPH diagnosis compared between sexes with a 2-tailed Student t test. Sex differences in diagnostic timing and 3-month postoperative outcomes (gait, cognition, and UI) were analyzed with χ2 tests.</p><p><strong>Results: </strong>Eighty-two patients (38 male and 44 female) were included in the analysis. Females experienced a longer time to diagnosis than males (40.3 vs 16.8 mo; P=0.001). Following surgery, no significant sex differences were observed in gait (P=0.32), cognitive (P=0.17), or UI improvement (P=0.11), but females had lower rates of complete UI resolution (13.6% vs 36.8%; P=0.020). In females, but not males, 3-month UI improvement (12.5 vs 46.8 mo; P=0.02) and resolution (1.7 vs 35.4 mo; P=0.002) correlated with shorter time to diagnosis.</p><p><strong>Conclusions: </strong>Females with UI face a longer time to iNPH diagnosis and lower rates of complete symptom resolution. Increased awareness of iNPH in this population is essential for timely screening and improved outcomes.</p>","PeriodicalId":75288,"journal":{"name":"Urogynecology (Hagerstown, Md.)","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145202402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inpatient Mortality Among U.S. Women Treated for Urinary Tract Infection 2016-2020.","authors":"Gabriella Rustia, Megan Abrams, Stephen Rhodes, Adonis Hijaz, David Sheyn","doi":"10.1097/SPV.0000000000001756","DOIUrl":"https://doi.org/10.1097/SPV.0000000000001756","url":null,"abstract":"<p><strong>Importance: </strong>Urinary tract infections in adult women are commonlytreated by gynecologists and urologists.</p><p><strong>Objective: </strong>The objective of this study was to estimate the frequency of and factors associated with mortality among women hospitalized with a primary diagnosis of a urinary tract infection (UTI).</p><p><strong>Study design: </strong>This was a retrospective cohort study using the National Inpatient Sample of adult women hospitalized with a UTI between 2016 and 2020. Patients' demographic, hospital-level data, comorbidities, and associated diagnoses were identified using International Classification of Diseases, Tenth Revision, (ICD-10) codes. The primary outcome was death during hospitalization. Independent associations with death were analyzed using multivariable logistic regression of variables that occurred in 2% or more of hospitalizations (irrespective of outcome).</p><p><strong>Results: </strong>A total of 330,905 hospitalizations with a primary diagnosis of UTI were identified, including 1,588 deaths (0.48%). Death was most strongly correlated with increasing age: above 85 years (adjusted odds ratio [aOR], 8.37; 95% CI, 5.69-12.30), age 76-85 years (aOR, 5.63; 95% CI, 3.83-8.27), age 66-75 years (aOR, 4.45; 95% CI, 3.01-6.57), age 51-65 years (aOR, 3.17; 95% CI, 2.12-4.73) compared with those 18-50 years. The comorbidities and diagnoses most associated with death included metastatic cancer (aOR, 4.25; 95% CI, 3.50-5.16), pneumonia (aOR, 3.68; 95% CI, 3.17-4.28), and weight loss (aOR, 2.98; 95% CI, 2.65-3.36). Bacteremia (aOR, 0.65; 95% CI, 0.45-0.95), complicated hypertension (aOR, 0.61; 95% CI, 0.52-0.72), depression (aOR, 0.75; 95% CI, 0.65-0.87), and nutritional anemia (aOR, 0.76; 95% CI, 0.60-0.96) were most associated with a decreased probability of death.</p><p><strong>Conclusion: </strong>Death during hospitalization for a diagnosis of UTI was rare, even in critically ill and extremely elderly patients.</p>","PeriodicalId":75288,"journal":{"name":"Urogynecology (Hagerstown, Md.)","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145202373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phenotype Variability in Interstitial Cystitis Clinical Trial Recruitment.","authors":"Ryan Wong, Emmaline Woodworth, Charles Wood, Sarah A Adelstein, Annah J Vollstedt","doi":"10.1097/SPV.0000000000001759","DOIUrl":"10.1097/SPV.0000000000001759","url":null,"abstract":"<p><strong>Importance: </strong>There is a need to understand phenotype-specific therapies for interstitial cystitis/bladder pain syndrome (IC/BPS) at the clinical trial level to move beyond trial-and-error treatment approaches.</p><p><strong>Objective: </strong>The objective of this study was to characterize IC/BPS clinical trials that incorporate patient phenotype into the eligibility criteria in accordance with the American Urological Association (AUA) guidelines.</p><p><strong>Study design: </strong>Registered IC/BPS clinical trials were identified from ClinicalTrials.gov. Trials were included if they enrolled patients with IC/BPS and addressed pain-related outcomes. Trials were assessed for phenotype recognition and categorized by intervention type, funding source, and registration date relative to the AUA's 2015 IC/BPS guidelines for initial phenotype recognition.</p><p><strong>Results: </strong>Out of 170 trials, 37 (21.8%) included phenotype stratification. The majority focused on bladder-centric presentations. Men were underrepresented in IC/BPS clinical trials. Phenotypic stratification was more frequently reported in industry-funded trials compared with those without industry support (40.5% vs 16.5%, P =0.0031). Trials registered after the 2015 AUA guideline update showed greater phenotype inclusion, though this was not statistically significant (26.6% vs 15.8%). Therapeutic trials comprised the majority of trials. Stratification appeared more often in physical therapy and psychosocial trials at 40% and in drug studies at 34.3%. Intravesical instillation and injection trials showed lower rates at 19.6% and 13.0%, respectively.</p><p><strong>Conclusions: </strong>Failure to incorporate IC/BPS phenotypes into trial design limits the ability to evaluate treatments within the context of real-world symptom variability. Bridging this methodological gap is essential to ensure that clinical research supports the development of more targeted and effective therapies.</p>","PeriodicalId":75288,"journal":{"name":"Urogynecology (Hagerstown, Md.)","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145202424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Executive Summary: The AUA/SUFU/AUGS Guideline on Genitourinary Syndrome of Menopause.","authors":"Melissa R Kaufman, A Lenore Ackerman, Katherine A Amin, Marge Coffey, Elisheva Danan, Stephanie S Faubion, Anne Hardart, Irwin Goldstein, Giulia M Ippolito, Gina M Northington, Charles R Powell, Rachel S Rubin, O Lenaine Westney, Tracey S Wilson, Una J Lee","doi":"10.1097/SPV.0000000000001753","DOIUrl":"10.1097/SPV.0000000000001753","url":null,"abstract":"<p><strong>Purpose: </strong>Genitourinary syndrome of menopause (GSM) describes the symptoms and physical changes that result from declining estrogen and androgen concentrations in the genitourinary tract during the menopausal transition. This guideline provides information to clinicians regarding identification, diagnosis, counseling, and treatment for patients with GSM to optimize symptom control and quality of life while minimizing adverse events.</p><p><strong>Methods: </strong>The systematic review used in the creation of this guideline is based on research conducted by the Minnesota Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality and funded by the Patient Centered Outcomes Research Institute. The EPC synthesized effectiveness and/or harms outcomes from 68 publications. An additional 66 articles evaluating 46 nonhormonal interventions were described in an evidence map.</p><p><strong>Results: </strong>Clinicians diagnose GSM based on symptoms, with or without related physical findings, and after ruling out other etiologies or co-occurring pathologies. There is a large body of evidence examining the use of hormonal and nonhormonal treatment options to manage the symptoms of GSM; however, the local low-dose vaginal estrogen has the most robust evidence base.</p><p><strong>Conclusion: </strong>The strategies defined in this document were derived from evidence-based and consensus-based processes. Given that there is insufficient information to recommend one hormonal therapy over another, this guideline is not meant to support a stepwise progression through different hormonal approaches. The clinician should make treatment decisions in the context of shared decision-making, considering patient goals and preferences, using the evidence of efficacy and adverse events of each possible intervention as a guide.</p>","PeriodicalId":75288,"journal":{"name":"Urogynecology (Hagerstown, Md.)","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145202415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Coding for Sacral Neuromodulation: Developed by the AUGS Coding Committee.","authors":"Jaclyn M Muñoz, Emily R W Davidson","doi":"10.1097/SPV.0000000000001758","DOIUrl":"https://doi.org/10.1097/SPV.0000000000001758","url":null,"abstract":"","PeriodicalId":75288,"journal":{"name":"Urogynecology (Hagerstown, Md.)","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145202431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Spatial Mapping of Pelvic Anatomy Focused on Vaginal Natural Orifice Transluminal Endoscopic Surgery (vNOTES) Apical Suspension Prolapse Procedures.","authors":"Dani Zoorob, Adegbenro O J Fakoya, Hosne Ara, Mathew Root, Michael Mahoney, Christopher Menefee, Kristy Waltman, Veronica Lerner","doi":"10.1097/SPV.0000000000001752","DOIUrl":"https://doi.org/10.1097/SPV.0000000000001752","url":null,"abstract":"<p><strong>Importance: </strong>Comprehensive understanding of anatomic landmarks is essential for safe and successful apical suspension during vaginal Natural Orifice Transluminal Endoscopic Surgery (vNOTES) procedures. However, detailed descriptions of these landmarks remain scarce in the current literature.</p><p><strong>Objective: </strong>We aimed to delineate the anatomic relationships of key landmarks relevant to apical suspension procedures performed through vNOTES.</p><p><strong>Study design: </strong>Ten embalmed female cadavers were dissected. A 9.5 cm Alexis retractor from the commercially manufactured vNOTES port was used. Distances were measured from the inner ring of the retractor to the following anatomic structures: the ischial spine (sagittal and transverse planes), S1 root, urethra, trigone, pubic crest, and iliac vessels.</p><p><strong>Results: </strong>The mean distance from the retractor's inner ring to the ischial spine was 1.0 cm (range: 0.9-1.3, SD: 0.1) sagittally and 3.6 cm (range: 3.0-4.9, SD: 0.6) transversely. The S1 foramen was located 6.4 cm (range: 5.0-8.0, SD: 1.0) from the ring's midpoint. Sagittal measurements revealed a mean distance of 2.6 cm (range: 1.7-3.5, SD: 1.0) from the proximal urethra and 1.9 cm (range: 1.4-3.5, SD: 0.7) from the trigone. The external iliac vessels were 3.2 cm (range: 2.1-4.1, SD: 0.7) from the ring's edge, while the pubic crest was 2.7 cm (range: 1.6-3.3, SD: 0.5) away.</p><p><strong>Conclusions: </strong>The spatial relationships described in this study provide crucial reference points for surgeons performing apical suspension during vNOTES. Knowledge of these relationships can enhance safety and provide a roadmap for future innovation and the advancement of complex gynecologic interventions.</p>","PeriodicalId":75288,"journal":{"name":"Urogynecology (Hagerstown, Md.)","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145133214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimal Anesthesia for Polyacrylamide Hydrogel Injection: A Randomized Trial.","authors":"Neha G Gaddam, Joanna Marantidis, Noha T Ahmed, Rachael D Sussman, Elizabeth T Brown, Alexis A Dieter, Andrew I Sokol, Robert E Gutman, Lee A Richter","doi":"10.1097/SPV.0000000000001757","DOIUrl":"https://doi.org/10.1097/SPV.0000000000001757","url":null,"abstract":"<p><strong>Importance: </strong>Despite the popularity of urethral bulking with polyacrylamide hydrogel (PAHG) for stress urinary incontinence (SUI)/intrinsic sphincter deficiency (ISD), no studies have assessed optimal anesthetic protocols.</p><p><strong>Objectives: </strong>To compare pain scores between 2 anesthetic protocols in women undergoing in-office PAHG injection: (1) combined anesthetic [external lidocaine-plus-prilocaine (EMLA) cream, intraurethral lidocaine gel, and lidocaine periurethral block] or (2) topical-only (external EMLA cream and intraurethral lidocaine gel).</p><p><strong>Study design: </strong>This single-blinded trial randomized women to 1 of 2 anesthetic protocols. The primary outcome was pain reported via a 10-point visual analog scale (VAS). Secondary outcomes included International Consultation on Incontinence Questionnaire-Urinary Incontinence (ICIQ-UI) and Patient Global Impression of Improvement (PGI-I) scores. A safety endpoint of 3 subjects in the topical-only arm requiring unplanned periurethral block to complete the PAHG procedure, and an a priori sample size of 52 subjects was set.</p><p><strong>Results: </strong>Recruitment stopped at 23 subjects (N=11 combined anesthetic vs. N=12 topical-only) upon meeting the safety endpoint. Mean procedural VAS pain scores were lower with concomitant periurethral block (4.5±2.7 combined anesthetic vs. 7.4±2.3 topical-only; P<0.01). For 3 subjects in the topical-only arm requiring additional anesthesia, VAS pain scores were reduced following periurethral block (10.0±0.0 preblock to 4.0±2.6 postblock; P=0.04). There was no difference between arms in procedure duration, reinjection, or questionnaire scores. Subjects in the combined anesthetic arm were less likely to require post-procedure straight catheterization (0% vs. 33% topical-only; P=0.04).</p><p><strong>Conclusions: </strong>Use of a periurethral block with topical anesthetics reduced pain scores and improved postprocedure voiding. These findings support using a combined anesthetic protocol for women undergoing in-office PAHG injection.</p>","PeriodicalId":75288,"journal":{"name":"Urogynecology (Hagerstown, Md.)","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145133208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Update on Single-incision Slings.","authors":"Omar Mesina, Emily S Lukacz","doi":"10.1097/SPV.0000000000001734","DOIUrl":"https://doi.org/10.1097/SPV.0000000000001734","url":null,"abstract":"<p><strong>Importance: </strong>Single-incision slings (SIS) offer a minimally invasive option for treating stress urinary incontinence (SUI), aiming to reduce operative time, postoperative pain, and recovery compared to traditional slings. Their growing use underscores the importance of understanding their effectiveness, safety profile, and long-term outcomes to ensure optimal patient care.</p><p><strong>Objective: </strong>The objective was to update current evidence on the safety, efficacy, and economic impact of SISs for the treatment of SUI in women.</p><p><strong>Study design: </strong>A structured literature review was conducted using PubMed, Cochrane Library, and the U.S. Food and Drug Administration (FDA) 522 Postmarket Surveillance Studies Database up to December 2024. Inclusion criteria were randomized controlled trials, prospective observational studies, meta-analyses and the FDA summary addressing SIS outcomes. Key metrics included objective and subjective cure rates, complications, and economic evaluations.</p><p><strong>Results: </strong>A total of 28 publications were reviewed since the most recent Cochrane review in 2023. Overall, high subjective (73.3% to 94.2%) and objective cure rates (61.5% to 94%) continue to be reported for SISs with operative times of 10.7 to 20.4 min and low adverse events of mesh complications (0% to 14.2%), reintervention procedures (0% to 16.3%) and de novo urgency urinary incontinence (0% to 15%) up to 36 months. Economic analyses revealed short-term cost savings for SISs, particularly in outpatient settings under local anesthesia, though cost-effectiveness over longer periods remains uncertain due to potential retreatment and/or complications.</p><p><strong>Conclusions: </strong>Single-incision slings offer a minimally invasive option for SUI with comparable efficacy to full-length midurethral slings, with rare perioperative complications and short operative times. Long-term outcomes on complications and durability are needed. Future studies are needed to guide clinical decision making, particularly regarding longer-term complications and cost-effectiveness.</p>","PeriodicalId":75288,"journal":{"name":"Urogynecology (Hagerstown, Md.)","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145202408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Racial Disparities in Nocturia Persist Regardless of BMI Among American Women.","authors":"Gnankang Sarah Napoe, Dulcie Kermah, Nia S Mitchell, Keith Norris","doi":"10.1097/SPV.0000000000001560","DOIUrl":"10.1097/SPV.0000000000001560","url":null,"abstract":"<p><strong>Importance: </strong>It is crucial to understand the racial and ethnic disparities that exist in nocturia prevalence to appropriately manage nocturia.</p><p><strong>Objectives: </strong>Nocturia is associated with increased body mass index (BMI) and is most prevalent in Black and Hispanic women, who also have the highest and second highest prevalence of obesity, respectively. We sought to better understand the association of nocturia with BMI category by race and ethnicity in U.S. women.</p><p><strong>Study design: </strong>This was a cross-sectional study using publicly available data from the National Health and Nutrition Examination Survey data from 2005 to 2018. We estimated the prevalence of moderate to severe nocturia (defined as 2 or more episodes of nighttime urination) by BMI category within each racial and ethnic (Black, White, Hispanic, and other) group of adult women. Logistic regression was performed to determine the odds ratio of nocturia by race.</p><p><strong>Results: </strong>The odds of nocturia was 2.25 (2.04-2.49) for Black women, 1.27 (1.15-1.4) for Hispanic women and 0.96 (0.82-1.13) for other women compared to White women. After accounting for BMI, socioeconomic status and comorbidities, the adjusted odds ratio was 1.76 (1.42-2.16) for Black women, 1.1 (.0.88-1.38) for Hispanic women, and 0.81 (0.5-1.29) for other women compared to White women.</p><p><strong>Conclusions: </strong>Black women were nearly twice as likely to have nocturia than White women. The increased odds of nocturia, while not sustained for Hispanic women, persisted for Black women regardless of socioeconomic status, BMI, and comorbidities. Our study suggests that there are factors other than weight driving the prevalence of nocturia in Black women that require further investigation.</p>","PeriodicalId":75288,"journal":{"name":"Urogynecology (Hagerstown, Md.)","volume":" ","pages":"799-806"},"PeriodicalIF":1.2,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11779969/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141794250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}